转移性三阴性炎性乳腺癌患者的免疫检查点抑制剂治疗(INCORPORATE):一项国际队列研究
这项国际多中心回顾性队列研究纳入41例转移性三阴性原发性炎性乳腺癌患者,评估免疫检查点抑制剂联合一线化疗的活性。中位随访19.3个月后,6个月真实世界无进展生存率为30%,中位真实世界无进展生存3.3个月,中位总生存15.7个月,提示该人群结局较差。
要点
- 41例转移性三阴性炎性乳腺癌患者接受免疫检查点抑制剂联合一线化疗。
- 6个月真实世界无进展生存率30%,中位真实世界无进展生存3.3个月。
- 中位总生存15.7个月,提示该人群结局较差。
核心结论
- 这项单样本分析显示,尽管接受免疫检查点抑制剂治疗,转移性三阴性炎性乳腺癌患者结局较差,与基于临床前免疫脆弱性证据预期的获益相反。
- 这些结果提示需要进一步研究免疫治疗在这一侵袭性且罕见的乳腺癌类型中的作用。
研究设计与样本
- 研究为多中心、国际、回顾性队列研究,评估免疫检查点抑制剂在转移性三阴性原发性炎性乳腺癌患者中的活性。
- 患者于2015年1月至2023年4月接受免疫检查点抑制剂联合一线化疗。
- 样本量42例可检测6个月真实世界无进展生存率从仅化疗的40%提高至免疫检查点抑制剂联合化疗的60%。
- 共纳入来自8个国际炎性乳腺癌转诊中心的41例患者,其中61%为原发性、新发转移性三阴性炎性乳腺癌,61%有内脏疾病。
- 所有患者接受免疫检查点抑制剂联合一线化疗,24%接受乳腺手术和/或局部区域放疗。
主要发现
- 中位随访19.3个月后,6个月真实世界无进展生存率为30%(95%置信区间[CI],17-45%)。
- 中位真实世界无进展生存为3.3个月(95% CI:2.2-5.4)。
- 中位总生存为15.7个月(95% CI:6.8-16.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive clinical presentation of breast cancer, recapitulating a specific biology with more immune-vulnerability than non-IBC. Patients with metastatic, triple-negative IBC (mTN-IBC) receive immune checkpoint inhibitors (ICIs) and chemotherapy, similarly to patients with triple-negative non-IBC. However, the benefit derived from ICI incorporation in this rare type of breast cancer is unknown. METHODS: We conducted a multicenter, international, retrospective, cohort study to evaluate the activity of ICIs in patients with metastatic, triple-negative, primary IBC, who received ICIs plus first line chemotherapy from January 2015 to April 2023. A sample size of 42 patients allowed to detect an increase in 6-months real-world progression-free survival (rwPFS) rate from 40 % with only chemotherapy to 60 % with ICI and chemotherapy. RESULTS: 41 patients from eight international IBC referral centers were included (61 % with primary, de novo mTN-IBC, 61 % with visceral disease). All received ICIs plus first line chemotherapy and 24 % underwent breast surgery and/or locoregional radiotherapy. After a median follow-up of 19.3 months, the 6-months rwPFS rate was 30 % (95 % Confidence Interval [CI], 17-45 %), the median rwPFS was 3.3 months (95 % CI: 2.2-5.4), the median overall survival was 15.7 months (95 % CI: 6.8-16.3). CONCLUSIONS: This one-sample analysis showed a poor outcome of patients with mTN-IBC, despite the treatment with ICI, in contrast with the expected benefit based on preclinical evidence of immune-vulnerability of IBC. These results suggest the need to further investigate the role of immunotherapy in this aggressive and rare type of breast cancer presentation.
引用
- Valenza C, Trapani D, Zagami P, et al. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. Eur J Cancer. 2024. PMID: 39486164. doi:10.1016/j.ejca.2024.115097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。